Insider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Sells 10,885 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 10,885 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the transaction, the chief executive officer now owns 430,931 shares of the company’s stock, valued at approximately $1,478,093.33. This represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $3.09 on Friday. The company’s 50 day moving average price is $4.30 and its 200-day moving average price is $5.55. Voyager Therapeutics, Inc. has a 52-week low of $2.95 and a 52-week high of $9.55. The company has a market capitalization of $170.59 million, a P/E ratio of 4.35 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the business earned $1.25 EPS. Analysts forecast that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on VYGR shares. Canaccord Genuity Group lowered their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Finally, StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $13.97.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in VYGR. Rhumbline Advisers increased its holdings in Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after purchasing an additional 2,354 shares in the last quarter. Empowered Funds LLC grew its position in shares of Voyager Therapeutics by 5.3% during the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company’s stock worth $268,000 after buying an additional 2,397 shares during the period. Wells Fargo & Company MN increased its stake in shares of Voyager Therapeutics by 3.7% in the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock valued at $378,000 after acquiring an additional 2,400 shares in the last quarter. Picton Mahoney Asset Management increased its stake in shares of Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after acquiring an additional 2,444 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after acquiring an additional 3,077 shares during the period. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.